JT Stratford LLC Takes $1.24 Million Position in Abbott Laboratories $ABT

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

JT Stratford LLC bought a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 9,379 shares of the healthcare product maker's stock, valued at approximately $1,244,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Hughes Financial Services LLC purchased a new stake in shares of Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories during the 1st quarter valued at approximately $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories during the 1st quarter valued at approximately $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories during the 1st quarter valued at approximately $32,000. Finally, Vision Financial Markets LLC purchased a new stake in Abbott Laboratories during the 1st quarter valued at approximately $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ABT shares. Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and increased their target price for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Raymond James Financial lowered their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. William Blair upgraded Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Royal Bank Of Canada raised their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Finally, Leerink Partners began coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $144.47.

Abbott Laboratories Stock Up 0.3%

NYSE:ABT traded up $0.4120 during mid-day trading on Friday, reaching $132.4120. The stock had a trading volume of 4,130,154 shares, compared to its average volume of 5,721,513. The company has a market capitalization of $230.46 billion, a price-to-earnings ratio of 16.59, a price-to-earnings-growth ratio of 2.50 and a beta of 0.70. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The stock's 50 day simple moving average is $131.08 and its two-hundred day simple moving average is $131.29. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the previous year, the firm posted $1.14 earnings per share. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were issued a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend was Tuesday, July 15th. Abbott Laboratories's payout ratio is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares of the company's stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.